Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.
about
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsA very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTPredictors of Treatment Failure among Adult Antiretroviral Treatment (ART) Clients in Bale Zone Hospitals, South Eastern EthiopiaDevelopment of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical PracticeClinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recoveryFactors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study.Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study.A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.Viral load as a surrogate end point in HIV disease.Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.Managing failure to antiretroviral drugs in HIV-1-infected patients.Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected womenAging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescentsImmunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy.Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failureIncreased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery.Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort StudyVirologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.Systemic Cytokine Levels Do Not Predict CD4(+) T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus InfectionHistory-adjusted marginal structural models for estimating time-varying effect modification.Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modificationRepositioning HIV protease inhibitors as cancer therapeuticsEfficacy of a clinical decision-support system in an HIV practice: a randomized trial.CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort.Harnessing the biology of IL-7 for therapeutic application.Immunodiscordant responses to HAART--mechanisms and consequences.Discordant responses to cART in HIV-1 patients in the era of high potency antiretroviral drugs: clinical evaluation, classification, management prospects.Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study.Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.Increased Regulatory T-Cell Percentage Contributes to Poor CD4(+) Lymphocytes Recovery: A 2-Year Prospective Study After Introduction of Antiretroviral Therapy.Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients.Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil.Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.
P2860
Q27021524-B25D7295-A320-49D2-B3BB-A0F3875BB878Q28542548-300577C0-9F2C-45B1-89E6-0C70920614FAQ28554591-F925879D-0307-4726-8EFD-8AC43207A764Q29036869-55F489A5-B0FE-403E-8E0A-4B45DD700B17Q33267347-EA90C344-0F45-41DB-A093-73720860FF0FQ33574798-237FD4AA-3C12-4310-B58B-9F80C31DBBA5Q33906239-E3FF1443-CA0F-45C1-963B-4D16C06100C3Q34043159-370FCD8D-7E5D-4F13-A7D4-BB3AE44958CAQ34065045-36CF3265-54A4-4CE5-9E89-91997155C1C8Q34332293-906CBFD4-6667-4D53-93E1-478FE9289DF2Q34438006-F0447706-258A-4995-8341-F702E0CE6F00Q34533854-16113D85-1963-405A-974E-9529C84179A8Q34546011-63A955F6-C883-40C9-A2F6-EB7BC7D5B2A7Q35063764-536E48F1-2061-4BE4-B268-2B06B17526AEQ35077997-2A32FEED-648E-4F14-AD11-321A72532567Q35088160-9A656EAC-3061-41B4-BD5E-A248DAEB8991Q35156558-48357598-9920-4388-85F5-59932384F199Q35338750-2D5C6EC8-3725-4C58-9940-4BE219F76C6AQ35366136-5B02ACA6-64B0-4B73-BFF7-EA4436AC8FA9Q35698801-F5396A65-BCBC-472B-8A9B-302AD4358020Q35856740-937D1B46-89D1-43D1-B8DB-D40D1B0A1FCBQ36082736-ACE539D6-EA00-415B-ADCC-62AD3185367BQ36263361-C8C052A7-73ED-47BF-8B3F-CE6DBD289073Q36661588-DB4BF27B-DA84-4FCD-9F66-435000D39D85Q36924003-16C3F38F-43CD-4706-AF67-85CF24B3DFD7Q37003795-73A1F0DB-70D6-46F0-A22E-085C4F918D9AQ37192579-BC89FEA3-15EC-4A68-ADA7-30F2400DAB32Q37313077-A9E171DB-FD52-4876-96D3-17A13B00F386Q37325907-B2B52C39-FD3E-458C-8C1B-CFA9B509BC92Q37617342-FFFECCBF-2A98-43C3-98B9-5812254558D5Q37867487-B85903C1-77F2-4C98-8736-2FB813FE62EBQ38156230-C2184758-FCC5-4567-A436-EA142EA58916Q38619193-F0FAE021-A0CE-4C7D-BCB7-8CBB0D802CF4Q39006642-0B3CB214-DC36-4E18-B089-E85209E7731FQ39347096-E63A9B93-EE57-4529-9AC7-B7DA8B16A167Q39422431-ABB8AF3B-6E72-48AD-870F-10195099A35CQ39422439-D91B6A45-7900-4BD6-9875-E1CEDC9C0558Q40919867-B1D6906A-0040-4724-B013-DD3F17F57950Q41857320-D1FDE394-F543-4A0C-88F9-9AD421A5C294Q43617569-82434A18-5A69-49A5-AD50-67F0F3FA4F76
P2860
Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Long-term clinical outcome of ...... inhibitor-containing regimen.
@en
Long-term clinical outcome of ...... inhibitor-containing regimen.
@nl
type
label
Long-term clinical outcome of ...... inhibitor-containing regimen.
@en
Long-term clinical outcome of ...... inhibitor-containing regimen.
@nl
prefLabel
Long-term clinical outcome of ...... inhibitor-containing regimen.
@en
Long-term clinical outcome of ...... inhibitor-containing regimen.
@nl
P2093
P356
P1476
Long-term clinical outcome of ...... inhibitor-containing regimen.
@en
P2093
P304
P356
10.1086/319861
P407
P577
2001-03-29T00:00:00Z